Havrix (Hepatitis A Vaccine (Inactivated)) - Summary

HAVRIX SUMMARY

HAVRIX (Hepatitis A Vaccine, Inactivated) is a noninfectious hepatitis A vaccine developed and manufactured by GlaxoSmithKline Biologicals. The virus (strain HM175) is propagated in MRC₅ human diploid cells. After removal of the cell culture medium, the cells are lysed to form a suspension. This suspension is purified through ultrafiltration and gel permeation chromatography procedures. Treatment of this lysate with formalin ensures viral inactivation. HAVRIX contains a sterile suspension of inactivated virus; viral antigen activity is referenced to a standard using an enzyme linked immunosorbent assay (ELISA), and is therefore expressed in terms of ELISA Units (EL.U.).

HAVRIX is indicated for active immunization of persons >/=2 years of age against disease caused by hepatitis A virus (HAV).

HAVRIX will not prevent hepatitis caused by other agents such as hepatitis B virus, hepatitis C virus, hepatitis E virus, or other pathogens known to infect the liver.

Immunization with HAVRIX is indicated for those people desiring protection against hepatitis A. Primary immunization should be completed at least 2 weeks prior to expected exposure to HAV.

HAVRIX NEWS HIGHLIGHTS

Media Articles Related to Havrix (Hepatitis A Vaccine)

Hepatitis A Vaccine Best Bet to Treat Virus
Source: MedicineNet Hepatitis Immunizations Specialty [2007.10.19]

more>>

Published Studies Related to Havrix (Hepatitis A Vaccine)

Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. [2008.05]

Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children. [2008.05]

Immunogenicity and safety of three consecutive lots of a new preservative-free inactivated hepatitis A vaccine (Healive): a double-blind, randomized and controlled trial. [2008.04.24]

Long-term antibody persistence induced by a combined hepatitis A and B vaccine in children and adolescents. [2008.03.25]

Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. [2008.03.04]

more>>

Clinical Trials Related to Havrix (Hepatitis A Vaccine)

Phase III, Open, Comparative Study in Healthy Adults Aged 18-50 Years Administered With Hepatyrix or Havrix + Typherix or Tiphim Vi, to Compare Reactogenicity and Immunogenicity. [Active, not recruiting]

Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella [Oka/Merck] Virus Vaccine Live Safety Study [Completed]

Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age [Completed]

Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Measles/Mumps/Rubella Vaccine & a Varicella (Chickenpox) Vaccine in Healthy Children [Active, not recruiting]

Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Diphtheria, Tetanus & Pertussis Vaccine (DTaP) Vaccine & a Haemophilus Influenza Type B (Hib) Vaccine in Healthy Children 15 m of Age [Completed]

more>>